From Casetext: Smarter Legal Research

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Oct 8, 2002
MDL-1290 (TFH/JMF), Misc. No. 99-276 CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Oct. 8, 2002)

Opinion

MDL-1290 (TFH/JMF), Misc. No. 99-276 CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.)

October 8, 2002


STIPULATION and ORDER


Walgreen Company ("Walgreen") defendants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc. (collectively, "Mylan"), through counsel, hereby agree and stipulate as follows with respect to Walgreen's Motion to Quash Subpoenas or, in the Alternative, for Protective Order, which was filed on September 18, 2002:

1. The deadline for the opposition to the motion shall be October 15, 2002.

2. The deadline for the reply in support of the motion shall be October 29, 2002.

3. Walgreen and Mylan will continue to discuss the issues raised in the motion in an effort to eliminate any dispute and resolve the matter without court intervention.


Summaries of

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Oct 8, 2002
MDL-1290 (TFH/JMF), Misc. No. 99-276 CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Oct. 8, 2002)
Case details for

In re Lorazepam Clorazepate Antitrust Litigation

Case Details

Full title:IN RE LORAZEPAM CLORAZEPATE ANTITRUST LITIGATION. This document relates…

Court:United States District Court, D. Columbia

Date published: Oct 8, 2002

Citations

MDL-1290 (TFH/JMF), Misc. No. 99-276 CV 1:99-790 (TFH/JMF), CV 1:99-2228 (N.D. Ill.) (D.D.C. Oct. 8, 2002)